North of England and Scotland Study of Tonsillectomy and Adeno-tonsillectomy in Children (NESSTAC): a pragmatic randomised controlled trial with a parallel non-randomised preference study

C Lock,1* J Wilson,1,2 N Steen,1 M Eccles,1 H Mason,1 S Carrie,2 R Clarke,3 H Kubba,4 C Raine,5 A Zarod,6 K Brittain,1 A Vanoli1 and J Bond1

1Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK
2ENT Department, Freeman Hospital, Newcastle upon Tyne, UK
3ENT Department, Alder Hey Children’s Hospital, Liverpool, UK
4ENT Department, Royal Hospital for Sick Children, Glasgow, UK
5ENT Department, Bradford Royal Infirmary, Bradford, UK
6ENT Department, Booth Hall Children’s Hospital, Manchester, UK

*Corresponding author

Executive summary

Health Technology Assessment 2010; Vol. 14: No. 13
DOI: 10.3310/hta14130
Executive summary

Background

Tonsillectomy and adeno-tonsillectomy have been widely used surgical procedures for the treatment of children with recurrent sore throat in the UK. The incidence of tonsillectomy has declined in recent years to some 50,000 tonsillectomy procedures carried out on children per year. There remains little clear evidence of clinical effectiveness and cost-effectiveness of surgical or medical management (Burton et al., 2008) that would guide clinicians in treatment decisions or commissioners in commissioning decisions.

Objectives

To examine the cost-effectiveness of tonsillectomy/adeno-tonsillectomy in children aged 4–15 years with recurrent sore throats in comparison with standard non-surgical management.

Design

A pragmatic randomised controlled trial with economic analysis comparing surgical intervention with conventional medical treatment in children with recurrent sore throats (trial) and a parallel non-randomised cohort study (cohort study).

Setting

Five secondary care otolaryngology departments located in the north of England or west of Scotland.

Participants

Two hundred and sixty-eight (trial) and 461 (cohort study) children aged between 4 and 15 years on their last birthday with recurrent sore throats.

Interventions

The treatment arm consisted of tonsillectomy and adeno-tonsillectomy with adenoid curettage and tonsillectomy by dissection or bipolar diathermy according to surgical preference within 12 weeks of randomisation. The control arm consisted of non-surgical conventional medical treatment only.

Main outcome measures

The primary clinical outcome was the reported number of episodes of sore throat in the 2 years after entry into the study. Secondary clinical outcomes included: the reported number of episodes of sore throat; number of sore throat-related GP consultations; reported number of symptom-free days; reported severity of sore throats; and surgical and anaesthetic morbidity. In addition to the measurement of these clinical outcomes, the impact of the treatment on costs and quality of life was assessed.

Analysis

An intention-to-treat analysis was performed according to the original protocol.

Economic evaluation

An intention-to-treat cost-effectiveness analysis, willingness-to-pay survey and cost–utility analysis were undertaken to estimate the incremental cost-effectiveness ratio, how much parents would be willing to pay and the incremental quality-adjusted life-years (QALYs) gained.

Results

Of the 1546 children assessed for eligibility, 817 were excluded (531 not meeting inclusion criteria, 286 refused) and 729 enrolled to the trial (268) or cohort (461).

Patient preferences

Sixty-three per cent (461/729) of children and parents participating in the study stated a preference for medical or surgical management: 16% (74/461) of these who were recruited to
the cohort study opted for continuing medical management and 84% (387/461) for surgical management. Prior to recruitment to the cohort study, participants opting for surgical management reported more sore throat episodes and that progress at school was impeded compared with cohort participants opting for medical management and trial participants.

Response rates at baseline and outcome

Eighty-eight per cent (642/729) of all study participants completed and returned baseline questionnaires. The response rate to self-completed outcome questionnaires was 56% at 3 months, 38% at 12 months and 33% at 24 months. At 12 months, the response was 48% for the trial and 33% for the cohort; at 24 months, trial response was 44% and cohort 27%. Each participant was sent 24 4-weekly diaries; there was a poor diary response rate: trial 41% and cohort 29%. The mean number of diaries returned per child was 9.9 for the trial and 6.8 for the cohort. The percentage of GP records accessed was 69 for the trial and 31 for the cohort.

Primary outcome

The primary outcome was the number of episodes of sore throat experienced during 2 years of follow-up by each participating child recorded each day in health diaries. The mean (standard deviation) episode of sore throats per month differed between years and treatment groups, and was in year 1: cohort medical 0.59 (0.44); cohort surgical 0.71 (0.50); trial medical 0.64 (0.49); and trial surgical 0.50 (0.43). Year 2: cohort medical 0.38 (0.34); cohort surgical 0.19 (0.36); trial medical 0.33 (0.43); and trial surgical 0.13 (0.21). During both years of follow-up, children randomised to surgical management were less likely to record episodes of sore throat than those randomised to medical management; the incidence rate ratios in year 1 and year 2 were 0.70 [95% confidence interval (CI) 0.61 to 0.80] and 0.54 (95% CI 0.42 to 0.70) respectively.

Secondary outcomes

The mean (standard deviation) number of sore throats differed between years and treatment groups, and was: year 1: cohort medical 30.6 (28.7); cohort surgical 42.8 (7.5); trial medical 49.1 (7.3); and trial surgical 31.0 (5.0). Year 2: cohort medical 20.4 (2.5); cohort surgical 10.5 (1.5); trial medical 20.2 (3.2); and trial surgical 8.0 (0.9). During both years of follow-up, children randomised to surgical management recorded less sore throats than children randomised to medical management; the incidence rate ratios were: year 1: 0.67 (95% CI 0.52 to 0.85) and year 2: 0.27 (95% CI 0.16 to 0.46).

The mean (standard deviation) number of recorded GP consultations for sore throats differed between years and treatment groups. Year 1: cohort medical 1.6 (2.0); cohort surgical 1.9 (2.2); trial medical 2.4 (2.4); and trial surgical 1.9 (2.8). Year 2: cohort medical 1.5 (2.1); cohort surgical 0.8 (1.3); trial medical 1.3 (1.6); and trial surgical 0.9 (1.4). During both years of follow-up, children randomised to surgical management recorded less sore throat-related consultations than children randomised to medical management; the incidence rate ratios were: year 1: 0.81 (95% CI 0.59 to 1.10) and year 2: 0.67 (95% CI 0.46 to 0.97).

The incremental cost-effectiveness ratio was estimated as £261 per sore throat avoided (95% CI £161 to £586). Parents were willing to pay for the successful treatment of their child’s recurrent sore throat (mean £8059). The estimated incremental cost per QALY ranged from £3129 to £6904 per QALY gained.

Conclusions

Children and parents exhibited strong preferences for the surgical management of recurrent sore throats. The health of all children with recurrent sore throat improves over time, but trial participants randomised to surgical management tended to experience better outcomes than those randomised to medical management. The limitations of the study due to poor response at follow-up support the continuing careful use of ‘watchful waiting’ and medical management in both primary and secondary care in line with current clinical guidelines until clear-cut evidence of clinical effectiveness and cost-effectiveness is available.

Implications for practice

- There are clinical benefits of tonsillectomy that persist for at least 2 years.
- Participants were more likely to express a preference for tonsillectomy if they had experienced more severe symptoms of sore throat.
Executive summary: North of England and Scotland Study of Tonsillectomy and Adeno-tonsillectomy in Children

• There is a strong parental preference for tonsillectomy.
• The findings support careful use of 'watchful waiting' and medical management in both primary and secondary care until clear-cut evidence of effectiveness is available.

Recommendations for research

• Exploratory secondary analysis to estimate the impact at surgical management on study participants whose tonsils were surgically removed.
• Methodological research of alternative methods of data collection.
• Larger utility elicitation/willingness-to-pay studies.

Trial registration

This trial is registered as ISRCTN47891548.

Publication

How to obtain copies of this and other HTA programme reports

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).

Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.

How to order:
– fax (with credit card details)
– post (with credit card details or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you to either print out your order or download a blank order form.

Contact details are as follows:
Synergie UK (HTA Department) Email: orders@hta.ac.uk
Digital House, The Loddon Centre Tel: 0845 812 4000 – ask for ‘HTA Payment Services’
Wade Road (out-of-hours answer-phone service)
Basingstoke Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header
Hants RG24 8QW

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.

Paying by credit card
You can order using your credit card by phone, fax or post.

Subscriptions

NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

How do I get a copy of HTA on DVD?

Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series *Health Technology Assessment*.

**Criteria for inclusion in the HTA journal series**

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.